CLDX

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a biopharmaceutical company founded in 1983 and headquartered in Hampton, New Jersey. The company went public in 1986 and has spent nearly four decades developing innovative antibody-based therapies for cancer and inflammatory diseases. Celldex specializes in creating monoclonal and bispecific antibodies, which are sophisticated protein-based drugs designed to target specific disease mechanisms with high precision. The company operates as a clinical-stage biotechnology firm, meaning its drug candidates are currently undergoing human testing but have not yet received regulatory approval for commercial sale.